(Pembrolizumab+vibostolimab) is under clinical development by Merck and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase II drugs for Mantle Cell Lymphoma have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Pembrolizumab+vibostolimab)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MK-7684A is under development for the treatment of solid tumor including cervical cancer, hepatocellular carcinoma, endometrial cancer, biliary cancer, cholangiocarcinoma, adenocarcinoma of the gastroesophageal junction, non-small cell lung cancer, squamous non-small cell lung cancer, gallbladder cancer, esophageal cancer, head and neck cancer squamous cell carcinoma, esophageal squamous cell carcinoma, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, triple-negative breast cancer (TNBC), small cell lung carcinoma, transitional cell carcinoma (urothelial cell carcinoma), urothelial carcinoma of renal pelvis, ureter cancer, bladder cancer, urethral cancer, ovarian cancer, gastric cancer and hematological tumors including relapsed/refractory classic Hodgkins Lyphoma (cHL), Primary mediastinal B-cell lymphoma (PMBCL), Follicular Lymphoma (FL), Diffuse large B-cell lymphoma (DLBCL) or Non-Hodgkins Lymphoma (NHL), or multiple myeloma (MM), Mantle Cell Lymphoma and melanoma. It is a fixed dose formulation of pembrolizumab and vibostolimab and is administered through intravenous route. Pembrolizumab acts by targeting programmed cell death protein 1 (PD1) and vibostolimab by TIGIT protein.
Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
For a complete picture of (Pembrolizumab+vibostolimab)’s drug-specific PTSR and LoA scores, buy the report here.